US Bancorp DE Sells 7,851 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

US Bancorp DE lowered its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 36.4% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,726 shares of the medical research company's stock after selling 7,851 shares during the quarter. US Bancorp DE's holdings in Charles River Laboratories International were worth $2,704,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in CRL. Iridian Asset Management LLC CT lifted its holdings in Charles River Laboratories International by 19.2% in the third quarter. Iridian Asset Management LLC CT now owns 55,043 shares of the medical research company's stock worth $10,842,000 after acquiring an additional 8,876 shares during the last quarter. State of Alaska Department of Revenue increased its stake in shares of Charles River Laboratories International by 2.6% in the third quarter. State of Alaska Department of Revenue now owns 15,899 shares of the medical research company's stock valued at $3,131,000 after purchasing an additional 405 shares during the period. Clear Harbor Asset Management LLC bought a new stake in shares of Charles River Laboratories International during the third quarter valued at approximately $246,000. Forsta AP Fonden grew its holdings in Charles River Laboratories International by 11.6% in the 3rd quarter. Forsta AP Fonden now owns 10,600 shares of the medical research company's stock worth $2,088,000 after buying an additional 1,100 shares in the last quarter. Finally, E. Ohman J or Asset Management AB acquired a new stake in Charles River Laboratories International in the 3rd quarter valued at approximately $158,000. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Stock Up 13.5 %

CRL stock traded up $25.52 during mid-day trading on Wednesday, hitting $214.20. The stock had a trading volume of 2,275,034 shares, compared to its average volume of 614,799. The stock has a market capitalization of $11.06 billion, a price-to-earnings ratio of 25.59, a PEG ratio of 6.20 and a beta of 1.38. The company has a current ratio of 1.58, a quick ratio of 1.21 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a 1-year low of $166.87 and a 1-year high of $275.00. The company has a fifty day moving average of $192.99 and a 200 day moving average of $208.56.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.39 by $0.41. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. The firm had revenue of $1.03 billion during the quarter, compared to analysts' expectations of $1.03 billion. On average, equities analysts expect that Charles River Laboratories International, Inc. will post 10.01 EPS for the current fiscal year.

Charles River Laboratories International announced that its Board of Directors has authorized a share repurchase program on Wednesday, August 7th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 9.6% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company's board of directors believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. The Goldman Sachs Group decreased their target price on Charles River Laboratories International from $290.00 to $250.00 and set a "buy" rating on the stock in a report on Thursday, August 8th. UBS Group reduced their price objective on shares of Charles River Laboratories International from $290.00 to $240.00 and set a "buy" rating for the company in a research note on Thursday, August 8th. Bank of America downgraded shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $250.00 to $215.00 in a research report on Wednesday, October 2nd. Redburn Atlantic started coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They set a "sell" rating and a $151.00 price target on the stock. Finally, JPMorgan Chase & Co. lowered shares of Charles River Laboratories International from an "overweight" rating to a "neutral" rating and decreased their price objective for the stock from $270.00 to $205.00 in a research note on Thursday, August 8th. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $209.00.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).